Anebulo Pharmaceuticals, Inc. (ANEB) — 10-Q Filings

10-Q Filings (6)

• Anebulo Narrows Q1 Loss to $2.16M Amid R&D Cuts — Nov 13, 2025 Risk: high
  Anebulo Pharmaceuticals, Inc. reported a net loss of $2.16 million for the three months ended September 30, 2025, a slight improvement from the $2.20 million ne
• Anebulo Pharmaceuticals Files 10-Q for Q3 2025 — May 13, 2025 Risk: medium
  Anebulo Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company, operating in pharmaceutical preparations, reported its financial s
• Anebulo Pharmaceuticals Files Q2 2025 10-Q — Feb 14, 2025 Risk: medium
  Anebulo Pharmaceuticals, Inc. filed a 10-Q for the period ending December 31, 2024. The filing covers the second quarter of their fiscal year. Key financial dat
• Anebulo Pharmaceuticals Files Q1 2025 10-Q — Nov 13, 2024 Risk: medium
  Anebulo Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the first quarter of fisca
• Anebulo Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Anebulo Pharmaceuticals, Inc. (ANEB) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Anebulo Pharmaceuticals, Inc. filed a 10-Q report for the per
• Anebulo Pharmaceuticals, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 13, 2024 Risk:
  Anebulo Pharmaceuticals, Inc. (ANEB) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Anebulo Pharmaceuticals, Inc. filed a 10-Q report for th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX